Take a look at some of Monday's morning movers:
JPMorgan Chase - Multiple reports saying three top executives are expected to leave this week in the aftermath of the bank’s
Yahoo - CEO Scott Thompson has resigned and activist hedge fund Third Point has gained three seats on the Yahoo board. Additionally, chairman Roy Bostock has been replaced by Fred Amoroso, the board member who led the investigation into Thompson's resume discrepancies.
Chesapeake Energy - The Wall Street Journal is reporting that investor Carl Icahn is expected to disclose a stake in the natural gas company "soon." CNBC's David Faber had reported this several weeks ago. The stock has fallen to its lowest level in about three years, following Friday’s revelation that the company may have to delay asset sales to stay in compliance with the terms of its credit line.
American Airlines - The airline has agreed with its creditors on
Nokia - Societe General has cut its rating on Nokia to “sell” from “hold,” forecasting a significant drop in handset sales. The SocGen report says if Nokia experiences the kind of sales drop seen by rival Motorola Mobility , it could burn through most of Nokia’s existing cash.
BHP Billiton - The company says it will decide by June 30 whether to write down the value of its U.S. shale gas assets, in the wake of slumping natural gas prices. BHP owns more than 1.6 million acres in shale assets in Texas, Louisiana, and Arkansas.
Avon Products - Avon says it will consider Coty’s latest $10.7 billion takeover bid and plans to respond within a week. Coty had originally given Avon a deadline of today to respond to its improved offer of $24.75 per share, and has reached out to Avon for clarification on why it's asking for more time.
Symantec - The anti-virus software maker's shares have been downgraded to "sell" from "neutral" by Goldman Sachs, with a price target of $14. Goldman cites shrinking profit margins and worsening cash flow.
St. Jude Medical -Goldman Sachs has upgraded St. Jude shares to "buy" from "neutral," and raised the price target to $50 from $45. Goldman says St. Jude is gaining share in its core markets, as well as experiencing success in new therapeutic categories.
—By CNBC’s Peter Schacknow
Questions? Comments? Email us at firstname.lastname@example.org